Adaptive Biotechnologies COO exercises $12.14 options

Q: How many options did ADPT's President and COO exercise?

Julie Rubinstein exercised 11,881 options on November 9 and 11,881 options on November 10, each at an exercise price of $12.14 per share. The options were fully vested and exercisable and have an expiration date of March 4, 2032.

Both days' transactions were effected under a Rule 10b5-1 trading plan adopted November 18, 2025.

Available on EDGAR 11/10/2026 - 07:26 PM EST Accepted by SEC EDGAR 11/10/2026 - 07:26 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp President and COO Julie Rubinstein exercised 11,881 options at $12.14 per share on November 9 and another 11,881 on November 10, acquiring common shares. On November 9, she sold 1,100 shares at a weighted average price of $28.87, 8,381 at $30.15 and 2,400 at $30.58. On November 10, she sold 9,981 shares at $29.35 and 1,900 at $30.41. The transactions were made under a Rule 10b5-1 plan adopted November 18, 2025. The options were fully vested and exercisable and expire March 4, 2032.

Insider Trade Summary 10b5-1

Exercise and Sale: 23,762 shares ($420K approx. pre-tax spread)

Exercise and Sale 9 txns

Insider RUBINSTEIN JULIE

Role President and COO

Sold 23,762 shs ($709K)

Approx. gross sale proceeds $709K

Approx. exercise cost $288K

Approx. pre-tax spread $420K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) ^{F1, F7}	11,881	$0.00	$0.00
Exercise	Common Stock ^F1	11,881	$12.14	$144K
Sale	Common Stock ^{F1, F5}	9,981	$29.35	$293K
Sale	Common Stock ^{F1, F6}	1,900	$30.41	$58K
Exercise	Stock Option (right to buy) ^{F1, F7}	11,881	$0.00	$0.00
Exercise	Common Stock ^F1	11,881	$12.14	$144K
Sale	Common Stock ^{F1, F2}	1,100	$28.87	$32K
Sale	Common Stock ^{F1, F3}	8,381	$30.15	$253K
Sale	Common Stock ^{F1, F4}	2,400	$30.58	$73K

Holdings After Transaction: Stock Option (right to buy) — 35,228 options (Direct); Common Stock — 377,802 shares (Direct)

Footnotes (7)

F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.41 to $29.35, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.49, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.50 to $30.71, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.95, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F6. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.22 to $30.68, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F7. The option is fully vested and exercisable.

Key Figures

Options exercised: 11,881 options Options exercised: 11,881 options Exercise price: $12.14 per share +5 more

8 metrics

Options exercised 11,881 options November 9, 2026

Options exercised 11,881 options November 10, 2026

Exercise price $12.14 per share Options exercised on November 9 and November 10, 2026

Weighted average sale price $28.87 per share; 1,100 shares November 9, 2026

Weighted average sale price $30.15 per share; 8,381 shares November 9, 2026

Weighted average sale price $30.58 per share; 2,400 shares November 9, 2026

Weighted average sale price $29.35 per share; 9,981 shares November 10, 2026

Weighted average sale price $30.41 per share; 1,900 shares November 10, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average price, fully vested and exercisable

3 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported for this transaction is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

fully vested and exercisable financial

"The option is fully vested and exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did ADPT's President and COO exercise?

Julie Rubinstein exercised 11,881 options on November 9 and 11,881 options on November 10, each at an exercise price of $12.14 per share. The options were fully vested and exercisable and have an expiration date of March 4, 2032.

How many ADPT shares did Julie Rubinstein sell, and at what prices?

On November 9, Julie Rubinstein sold 1,100 shares at a weighted average price of $28.87, 8,381 at $30.15 and 2,400 at $30.58. On November 10, she sold 9,981 shares at $29.35 and 1,900 at $30.41; each reported sale price was a weighted average.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RUBINSTEIN JULIE

(Last)

(First)

(Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE

WASHINGTON

98109

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/09/2026		M⁽¹⁾		11,881	A	$12.14	389,683	D
Common Stock	11/09/2026		S⁽¹⁾		1,100	D	$28.87⁽²⁾	388,583	D
Common Stock	11/09/2026		S⁽¹⁾		8,381	D	$30.15⁽³⁾	380,202	D
Common Stock	11/09/2026		S⁽¹⁾		2,400	D	$30.58⁽⁴⁾	377,802	D
Common Stock	11/10/2026		M⁽¹⁾		11,881	A	$12.14	389,683	D
Common Stock	11/10/2026		S⁽¹⁾		9,981	D	$29.35⁽⁵⁾	379,702	D
Common Stock	11/10/2026		S⁽¹⁾		1,900	D	$30.41⁽⁶⁾	377,802	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$12.14	11/09/2026		M⁽¹⁾			11,881	⁽⁷⁾	03/04/2032	Common Stock	11,881	$0	47,109	D
Stock Option (right to buy)	$12.14	11/10/2026		M⁽¹⁾			11,881	⁽⁷⁾	03/04/2032	Common Stock	11,881	$0	35,228	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.41 to $29.35, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.49, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.50 to $30.71, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

5. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.95, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

6. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.22 to $30.68, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

7. The option is fully vested and exercisable.

	/s/ Julie Rubinstein by Kyle Piskel, Attorney-in-Fact	11/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR